Dr. Hoenle AG (HNL) AI Stock Analysis

• Market Cap: €51.04M
• Dividend Yield: N/A
• Average Volume (3M): 6.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: -3.11%
• EPS Growth: 9.59%
• Country: DE
• Employees: 585
• Sector: Industrials
• Sector Strength: 84
• Industry: Electrical Equipment & Parts
• EPS (TTM): 0.05
• Shares Outstanding: 6,062,930
• 10 Day Avg. Volume: 6,860
• 30 Day Avg. Volume: 6,705
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €10.00
• Price Target Upside: 19.62% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: €8.00 ▼(-4.31% Downside)

Dr. Hoenle AG's stock score is primarily impacted by its weak financial performance and bearish technical indicators. The company's declining revenues and profitability issues are significant concerns, compounded by negative valuation metrics. Technical analysis suggests further downside potential, with the stock trading below key moving averages and showing oversold conditions. The absence of earnings call data and corporate events means these factors do not influence the score.

Dr. Hoenle AG Business Overview & Revenue Model

Company Description

Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, medical technology, optics and opto electronics, automotive, and glass processing. The Equipment & Systems segment engages in the drying of inks and coatings, curing of adhesives and plastics, disinfecting surfaces, and solar simulation. The Glass & Lamps segment offers quartz glass tubing and rods for the lamp, automotive, semiconductor, and fibre cable industries, as well as lamps for water disinfection, and the drying of coatings and adhesives. The company was founded in 1976 and is headquartered in Munich, Germany.

How the Company Makes Money

Dr. Hoenle AG generates revenue through the sale of its UV technology products and services. The company's key revenue streams include the manufacturing and distribution of UV curing systems, UV lamps, and accessories, which are essential for various industrial processes. Additionally, Dr. Hoenle AG earns from offering customized solutions and after-sales services. Significant partnerships with industries such as automotive, electronics, and healthcare further contribute to its earnings by expanding its market reach and driving demand for its advanced UV technologies.

Dr. Hoenle AG Financial Statement Overview

Summary

Dr. Hoenle AG faces significant financial challenges, with declining revenues and profitability issues impacting overall performance. The balance sheet reveals a dependence on debt, while cash flows show some positive trends but remain volatile. Improvement in revenue and profitability metrics would be crucial for a stronger financial position.

Income Statement

Dr. Hoenle AG's revenue has declined over recent periods, with a negative revenue growth rate from 2023 to 2024. The company has been consistently reporting net losses, reflected in a negative net profit margin and EBIT margin for the TTM. Both gross and EBITDA margins are under pressure, indicating profitability challenges.

Balance Sheet

The balance sheet shows a moderately high debt-to-equity ratio, indicating a reliance on debt financing. The return on equity is negative due to net losses, which poses a risk. However, the equity ratio remains relatively stable, suggesting a reasonable proportion of equity financing.

Cash Flow

The company has shown some improvement in free cash flow, moving from negative to positive territory. The operating cash flow to net income ratio is positive, indicating cash generation despite net losses. However, the free cash flow growth is inconsistent, highlighting volatility in cash management.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	98.73M	106.34M	116.09M	115.17M	93.88M
Gross Profit	57.99M	53.35M	69.28M	69.34M	60.54M
EBITDA	3.07M	779.00K	20.41M	14.02M	14.82M
Net Income	-13.28M	-11.01M	-13.36M	-4.82M	5.68M
Balance Sheet
Total Assets	155.38M	176.16M	195.46M	202.91M	196.20M
Cash, Cash Equivalents and Short-Term Investments	7.51M	9.32M	7.13M	12.07M	34.17M
Total Debt	53.24M	56.89M	59.53M	53.64M	46.41M
Total Liabilities	75.70M	80.02M	88.22M	91.78M	79.51M
Stockholders Equity	79.42M	95.82M	106.88M	110.72M	116.34M
Cash Flow
Free Cash Flow	3.44M	209.00K	-11.71M	-15.96M	-22.96M
Operating Cash Flow	5.53M	3.14M	-7.41M	1.13M	7.23M
Investing Cash Flow	-2.37M	2.65M	-1.69M	-24.50M	-30.74M
Financing Cash Flow	-4.90M	-3.42M	3.73M	1.25M	43.25M

Dr. Hoenle AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HNL, the sentiment is Negative. The current price of 8.36 is below the 20-day moving average (MA) of 9.40, below the 50-day MA of 9.59, and below the 200-day MA of 9.07, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 25.66 is Positive, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:HNL.

Dr. Hoenle AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	64 Neutral	$10.64B	16.01	5.48%	2.12%	2.72%	-24.90%
HNL	42 Neutral	€51.04M	―	-14.99%	―	-3.11%	9.59%
0N2B	―	€43.96M	21.26	-5.76%	―	―	―
0P5F	―	€38.62M	―		―	―	―
0FWF	―	€45.69M	5.36	8.05%	―	―	―
TSS	―	€69.38M	11.39	6.79%	―	―	―
ALXA	―	€57.96M	12.34	18.83%	―	―	―

Dr. Hoenle AG Corporate Events

Dr. Hönle AG Revises Financial Forecast for 2024/25

Dr. Hönle AG has adjusted its financial forecast for the fiscal year 2024/25, anticipating revenues between €92 million and €94 million, down from the previous year’s €98.7 million. Despite the lower revenue expectations, the company projects an operating result before depreciation and amortization (EBITDA) between €5 million and €6 million, thanks to cost-cutting measures. This adjustment reflects the company’s strategic response to current market conditions and aims to maintain operational efficiency, potentially impacting stakeholders and the company’s market positioning.

The most recent analyst rating on (DE:HNL) stock is a Buy with a EUR22.00 price target. To see the full list of analyst forecasts on Dr. Hoenle AG stock, see the DE:HNL Stock Forecast page.